Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is reporting fourth quarter earnings results on Monday 23rd November 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.12 per share.
For the full year, analysts predict revenues of $ 129.53 million, while looking forward to loss of $ 0.21 per share.
Previous Quarter Performance
Arrowhead Pharmaceuticals, Inc. recorded loss for the third quarter of $ 0.13 per share, from the revenue of $ 27.38 million. The consensus estimates are loss of $ 0.12 per share from $ 28.91 million in revenue. The bottom line results missed street analysts by $ 0.01 or 8.33 percent, at the same time, top line results fell short of analysts by $ 1.53 million or 5.29 percent.
Stock Performance
Shares of Arrowhead Pharmaceuticals, Inc. traded low $ -0.12 or -0.17 percent on Friday, reaching $ 68.80 with volume of 672.00 thousand shares. Arrowhead Pharmaceuticals, Inc. has traded high as $ 69.29 and has cracked $ 66.85 on the downward trend
According to the previous trading day, closing price of $ 68.80, representing a 253.25 % increase from the 52 week low of $ 19.51 and a 6.51 % decrease over the 52 week high of $ 73.72.
The company has a market capital of $ 7.04 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Arrowhead Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 23rd November 2020, to discuss its 4Q20 financial results with the investment community. The participants may dial, 855-215-6159 (United States) or 315-625-6887 Outside U.S., and the passcode is 8492751 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website arrowheadpharma.com
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The companys pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
